Navigation Links
The First Dedicated Breast Cancer Cell Line Transfection Reagent
Date:4/3/2013

MADISON, Wis., April 3, 2013 /PRNewswire/ -- Mirus Bio has expanded its transfection expertise with the development of the TransIT-BrCa Transfection Reagent a high performance, low toxicity, DNA transfection reagent specifically formulated for breast cancer cell types. This new reagent offers users:

  • Superior DNA Delivery—Achieve high expression levels in breast cancer cell types including: MCF-7, MDA-MB-231, MDA-MB-453, MDA-MB-468, T47D.
  • Formulated for Low Cellular Toxicity—Maintain cell density and reduce experimental biases due to toxicity.
  • Scientifically Proven—Developed by Mirus Bio scientists with nearly 2 decades of gene delivery expertise.

(Logo: http://photos.prnewswire.com/prnh/20100818/CG52502LOGO)

Mirus Bio is dedicated to advancing breast cancer research. In addition to providing scientists with state-of-the-art transfection reagents Mirus will donate a portion of every sale of TransIT-BrCa Transfection Reagent to the Breast Cancer Research Foundation.

Visit www.mirusbio.com for all your transfection needs including data, protocols, technical support or to place an order.

About Mirus Bio LLC –

ONE FOCUS: TRANSFECTION
Every transfection product offered by Mirus Bio is the result of scientific discovery and development from an in-house team of organic chemists, molecular biologists, cell biologists and biochemists. Almost two decades after its founding, transfection continues to be the focal point and passion of Mirus, giving researchers the most reliable products and expertise.


'/>"/>
SOURCE Mirus Bio LLC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. First Warning Systems, Inc., Appoints Veteran Medical Executive Royea as CEO
2. Seahorse Bioscience Launches First Product from the Partnership with Baystate Medical Center and UMass Amherst
3. First Time in Philadelphia Is a Success for Pittcon 2013 (Summary Report)
4. Epizyme Granted First Patent Covering Personalized Therapeutic Drug Candidate E7438
5. Medifirst Solutions, Inc. Announces Further Update To Shareholders
6. BioMed Realty Trust Declares First Quarter 2013 Common Stock Dividend
7. MiMedx Responds To Inquiries Regarding Trading Activity; Reiterates First Quarter And Full Year Goals
8. First-To-File Patent Law Is Now In Effect, But What Does it Mean?
9. First Southeast Venture Philanthropy Summit Set In NC
10. Rigaku Raman Unveils Upgraded FirstGuard Handheld Analyzer with Industry’s Only 1064nm Wavelength Capabilities
11. First 3D Heads-Up Cataract Surgery Performed in Asia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... SARASOTA, FL (PRWEB) , ... ... ... Inc. (RPS®) today announces publication of a United States multicenter, prospective clinical ... single use, disposable, point-of-care diagnostic test capable of identifying clinically significant acute ...
(Date:10/11/2017)... YORBA LINDA, CA (PRWEB) , ... October 11, ... ... adapted to upregulate any gene in its endogenous context, enabling overexpression experiments and ... activation (CRISPRa) system with small RNA guides is transformative for performing systematic gain-of-function ...
(Date:10/11/2017)... LAGUNA HILLS, Calif. , Oct. 11, 2017  SkylineDx ... London (ICR) and University of Leeds ... to risk-stratify patients with multiple myeloma (MM), in a multi-centric ... The University of Leeds is the ... UK, and ICR will perform the testing services to include ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that give ... Liposomal Nanoparticle), a technology developed in collaboration with Children’s Hospital Los Angeles ...
Breaking Biology Technology:
(Date:8/15/2017)... --  ivWatch LLC , a medical device company focused on improving ... of its ISO 13485 Certification, the global standard for medical device ... (ISO®). ... Monitoring device for the early detection of IV infiltrations. ... "This is an important milestone for ivWatch, as it ...
(Date:5/23/2017)...  Hunova, the first robotic gym for the rehabilitation and functional motor ... Genoa, Italy . The first 30 robots will be ... USA . The technology was developed and patented at the ... spin-off Movendo Technology thanks to a 10 million euro investment from entrepreneur ... ...
(Date:4/19/2017)... 19, 2017 The global military ... is marked by the presence of several large global ... by five major players - 3M Cogent, NEC Corporation, ... for nearly 61% of the global military biometric market ... the global military biometrics market boast global presence, which ...
Breaking Biology News(10 mins):